Viventia Biotechnologies Inc.

Viventia Bio Inc.

Merck Patent Gmbh

Other

Viventia Biotech Inc.

Francis J. Carr

Koen Hellendoorn

Nicholas Ronald Glover

Jeannick Cizeau

Joycelyn Entwistle

Glen Christopher Macdonald

Denis Georges Bosc

Matthew Baker

Francis Joseph Carr

Glen MacDonald

Francina C Chahal

Francis J Carr

Denis Bosc

Arjune Premsukh

Adrian Schwartz Mittelman

Shilpa Chooniedass

Nicholas R Glover

The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab', F(ab&#x2032;)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

Anti-EPCAM antibodies and methods of use

The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.

Methods for generating and screening fusion protein libraries and uses thereof

The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.

Antibody conjugates against variant NFKBIB and uses thereof

The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.

Tumor specific antibody

The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.

Cancer-associated antigen

The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.

Cytotoxins comprising modified bouganin toxin for the treatment of cancer

The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.

Cancer specific antibody and cell surface proteins

Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof

CD44E tumor specific antibody

An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the Vregion, Vregion, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in anexpression system.

Optimized nucleic acid sequences for the expression of VB4-845

The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.

Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof

An optimized nucleic acid sequence encoding the immunoconjugate VB6-845 is described Modifications to the original VB6-845 include changes in the nucleic acid sequence encoding the Vregion, Cregion, Cregion, Vregion, the furm linker and the bouganm toxin. The optimized VB6-845 displays improved recombinant protein expression over the original in anexpression system.

Binding proteins that bind to EpCAM linked to an effector molecule

Cancer associated glucose transporter 8 variant

The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits.

Growing community of inventors

Winnipeg, Canada

Jeannick Cizeau